Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Guangzhou Institute of Respiratory Disease
Age
4–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Enrolled patients were required to have been on regular ICS-LABA therapy for at least 3-6 months without adequate control. The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl. All children were prescribed with dupilumab during the study period.
You may not be if
Patients with conditions other than asthma receiving treatment with dupilumab, individuals currently using other biologics or undergoing sublingual or subcutaneous immunotherapy, active parasitic infections, and children with immunodeficiency were excluded.
Clareo Health | The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study
